Pancreatic Cancer-Induced Cachexia Is Jak2-Dependent in Mice

Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass

(2013) Liping Zhang et al.   Cell Metabolism

Muscle wasting in cancer

(2013) N. Johns et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia

(2012) Andrea Bonetto et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

(2012) Kenneth C.H. Fearon et al.   Cell Metabolism

Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer

(2012) Carla E. Cano et al.   EMBO Molecular Medicine

Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia

(2012) Katsutoshi Ando et al.   JOURNAL OF CLINICAL ONCOLOGY

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

(2011) Trevor J Bayliss et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia

(2011) Andrea Bonetto et al.   PLoS One

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer

(2008) Jeannine Bachmann et al.   JOURNAL OF GASTROINTESTINAL SURGERY